Oxaliplatin
- TRADE NAMES: Eloxatin (Sanofi-Aventis); Heloxatin
- INDICATIONS: Metastatic carcinoma of the colon or rectum (in combination with fluorouracil/leucovorin (FOLFOX; mFOLFOX6)). Advanced pancreatic cancer (in combination with irinotecan/fluorouracil/leucovorin (FOLFIRINOX or FOLFOXIRI)).
- CLASS: Alkylating agent, Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Platinum-based antineoplastic
- HALF-LIFE: 391 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Aminoglycosides, BCG Vaccine, Capreomycin, Cardiac glycosides, Clozapine, Denosumab, Diuretics, Leflunomide, Natalizumab, Pimecrolimus, Polymyxins, Sipuleucel-T, Tacrolimus, Taxanes, Topotecan, Trastuzumab, Vaccines, Vitamin K antagonists
PREGNANCY CATEGORY: D
ANAPHYLACTIC REACTIONS
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
HAIR.
NAILS.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
OTIC.
RENAL.
RESPIRATORY.
OTHER.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of oxaliplatin in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 04/05/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
